Antifungal activity study on HDAC inhibitor Rocilinostat / 药学实践杂志
Journal of Pharmaceutical Practice
; (6): 44-47, 2022.
Article
in Zh
| WPRIM
| ID: wpr-907153
Responsible library:
WPRO
ABSTRACT
Objective To evaluate the in vitro synergistic antifungal activity of HDAC inhibitors in combination with azole drugs against azoles-resistant Candida strains. Methods The checkerboard microdilution method was used to evaluate the antifungal activity of the HDAC inhibitors in combination with azole drugs against clinically drug-resistant strains. The fungistatic activity and toxicity of Rocilinostat was determined through time-growth curve assay and cytotoxicity assay. Results The compound Rocilinostat combined with azole drugs showed excellent synergistic antifungal activity against a variety of azoles-resistant Candida albicans and Candida glabrata. The combination of high concentration Rocilinostat with FLC exhibited fungistatic effects. Very low toxicity was detected with Rocilinostat towards normal cells. Rocilinostat showed better HDAC inhibitory activity than SAHA. Conclusion As a fungi HDAC inhibitor, Rocilinostat has excellent in vitro synergistic antifungal activity and no severe toxicity to normal human cells.
Full text:
1
Index:
WPRIM
Language:
Zh
Journal:
Journal of Pharmaceutical Practice
Year:
2022
Type:
Article